We are delighted to announce that InHealth will soon be launching the UK’s first relocatable Radioligand Therapy (RLT) service – a ground-breaking development in cancer care.
Radioligand Therapy, which is sometimes referred to as Molecular Radiotherapy (MRT), is a uniquely innovative approach to cancer treatment that, while already available in the UK at a very small number of static locations, is expected to play a much more integral role in cancer treatment in the near future.
RLT is a type of therapy that uses radiation to target cancer cells using specific molecules or ligands, and typically supports patients with neuroendocrine tumours and prostate cancer. At InHealth, our existing PET-CT service already supports over 20,000 UK cancer patients each year through both mobile and static sites, and what makes this brand new RLT service so unique and exciting is that we will be offering it through the world’s first relocatable facility.
Not only will this service provide additional capacity to existing sites that offer the care from acute hospitals and static locations, but since it can be moved and relocated on a daily basis, InHealth will be able to support patients in new and harder-to-reach locations, providing them a service that has never before been an option because of geographical constraints.
By combining this new therapy service with InHealth’s existing position as the UK’s largest specialist provider of diagnostic and healthcare solutions, we are proud to confirm our place at the forefront of innovations in therapy-based cancer patient diagnostics and treatment (also known as Theranostics).
For more information about InHealth’s new RLT service, please contact Ralph Toop, Director of Operations – PET-CT and Specialised Services.
We look forward to launching this service and supporting more patients by creating greater access through this specialised pathway.
More information can also be found at:
- Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumours (NETs) | Cancer Research UK
- Behind the headlines lutetium therapy | Prostate Cancer UK
- The BNMS Molecular Radiotherapy Group – British Nuclear Medicine Society